Clinical Trials in Tengzhou, China
1 recruiting
Showing 1–6 of 6 trials
Recruiting
Phase 2
Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma
HER2-negativeLow PD-L1 ExpressingUnresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Qilu Hospital of Shandong University77 enrolled29 locationsNCT06932068
Recruiting
Phase 3
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
Acute Ischemic Stroke
Boehringer Ingelheim1,325 enrolled224 locationsNCT07361302
Recruiting
Phase 2
Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke
Acute Ischemic Stroke
Kunming Pharmaceuticals, Inc.300 enrolled23 locationsNCT07279493
Recruiting
Phase 4
Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
Cardiac dysfunctionCoronary Heart Disease
SPH Qingdao Growful Pharmacetical Co.,Ltd2,708 enrolled96 locationsNCT07110415
Recruiting
Phase 2
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Metastatic Gastric CancerUnresectable Gastric CarcinomaHER2-positive Gastric Cancer
Qilu Hospital of Shandong University110 enrolled20 locationsNCT06730373
Recruiting
Phase 4
Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome
Chronic Coronary Syndrome
Shandong First Medical University1,200 enrolled32 locationsNCT06171061